cognitive disorders

H3 receptor-MO-1, a potent modulator of the histamine H3 receptor (H3 receptor), can be utilized to study neurodegeneration and cognitive disorders.

MK-0249 FA is an orally active, selective and potent histamine H3 inverse agonist for the study of attention deficit, hyperactivity disorder neurodivergent and cognitive disorders in adults.

NGD 94-1 is a selective D4 receptor antagonist with an affinity of 3 nM for the D4 receptor and greater than 2 pM for the D1, D2, D3, and D5 receptors.NGD 94-1 can be used in the study of cognitive disorders and other psychiatric disorders.

RS 56812 hydrochloride is a 5-HT3 receptor antagonist and agonist, and may be used in the study of cognitive disorders.

RS 56812 is a 5-HT3 receptor antagonist and agonist used in the study of cognitive disorders.

Dimiracetam (NT-11624) is an orally active anti-neuropathy compound that inhibits hypersensitivity and neurological alterations and may be used in the study of cognitive disorders, depression and neuropathic pain.

GSK-1034702 is an M1 mAChR agonist that improves cognitive deficits and may be useful in the study of neurologic disorders.

GSK-239512 is an antagonist of H3 receptor and can be used in studies about the treatment of cognitive dysfunction in neurodegenerative disorders.

Sabeluzole (R-58735) has antiepileptic and cognitive enhancing effects, inhibits neurotoxin-induced tau expression and cell death.Sabeluzole is protective against chlordiazepoxide-induced habituation disorders and may be useful in the study of Alzheimer's disease.

SSR180711 hydrochloride (SSR-180711A HCl) is a selective Alpha7 nicotinic acetylcholine partial agonist for the study of neurodegenerative and cognitive disorders.

CP-810123 is a new alpha 7 nAChR agonist for the treatment of cognitive impairment associated with psychiatric or neurological disorders such as schizophrenia and Alzheimer's disease.

L-Clausenamide is an alkaloid extracted from the leaves of the yellow bark (Clausena lansium (Lour) skeels) and can be used to improve cognitive function. L-Clausenamide inhibits beta-amyloid (Aβ) toxicity and prevents the formation of neurofibrillary tangles by inhibiting tau phosphorylation. L-Clausenamide has neuroprotective activity and can be used to modulate stimuli triggered by Aβ25-35. L-Clausenamide can be used to study neurological disorders like Alzheimer's disease.

Luvadaxistat (TAK-831) is an orally active, potent and highly selective inhibitor of D-amino acid oxidase (DAAO) with an IC50 value of 14 nM for the oxidative deamination of D-serine.Luvadaxistat is used in the study of schizophrenia and cognitive disorders.

Elziverine is an orally available small molecule calmodulin antagonist.Elziverine in vitro treatment inhibited Ca-loading-induced acanthocyte formation in SHRSP, WKY, and Wistar rats in a concentration-dependent manner.Elziverine can be used for the treatment of neurological disorders, and may be used for the study of cognitive disorders.

Piracetam (UCB-6215), a cyclic derivative of the neurotransmitter gamma-aminobutyric acid (GABA), is used in therapy of the extensive cognitive disorders.

Guanfacine hydrochloride (Intuniv) is a centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.

sn-Glycero-3-phosphocholine (Choline glycerophosphate) is a natural choline compound found in the brain and in milk. It is also a parasympathomimetic acetylcholine precursor which may have a potential for the treatment of Alzheimer's disease and dementia. sn-Glycero-3-phosphocholine rapidly delivers choline to the brain across the blood–brain barrier and is a biosynthetic precursor of the acetylcholine neurotransmitter. It is a non-prescription drug in most countries due to its Generally Recognised As Safe (GRAS) status [1]. Studies have investigated its efficacy for cognitive disorders including stroke and Alzheimer's disease. An Italian multicentre clinical trial on 2, 044 patients suffering from recent stroke were supplied Glycerylphosphorylcholine in doses of 1, 000 mg day for 28 days and 400 mg three times per day for the five ensuing months. The trial confirmed the therapeutic role of alpha-GPC on the cognitive recovery of patients based on four measurement scales, three of which reached statistical significance [2].

Cyclic N-Acetyl-D-mannosamine is a monosaccharide used as a precursor in the chemical or enzymatic synthesis of neuraminic acid found in glycolipids and glycoproteins.N-Acetyl-D-mannosamine is a specific substrate for the synthesis of n -acetylneuraminic acid, an essential precursor for bacterial podoplanar polysialic acid (PA).N-Acetyl-D-mannosamine is used in the synthesis of sialic acid. mannosamine is used in the synthesis of sialic acid. It is also an intermediate in the synthesis of many carbohydrate-derived bioactive compound families and drug candidates.N-Acetyl-D-mannosamine is used in the study of cognitive disorders and aging.

RO-275 is a selective HCN1 inhibitor with oral activity, also inhibiting HCN2, HCN3, and HCN4. It improves working memory and is used in research on cognitive disorders.

Pramiracetam (CI-879), derived from piracetam, is a more effective nootropic drug . According to reports, Pramiracetam improved cognitive defects related with traumatic brain wounds. Pramiracetam was also potent in the therapy of cognitive disorders of traumatic origins and cerebrovascular.

AQW051 (VQW-765) is an orally active alpha-7 nicotinic acetylcholine receptor (α7-nAChR) specific activator that interacts with recombinant human α7-nAChR expression (pKD value 7.56). Alpha7-nachr is considered an attractive target for the treatment of cognitive impairments associated with neurological disorders, so VQW-051 is often used in studies of anxiety disorders and acute anxiety.

CB1 antagonist 1 is a CB1 receptor antagonist, used in the research of obesity and metabolic syndrome, neuroinflammatory disorders, cognitive disorders, and gastrointestinal disorders, psychosis, and cardiovascular.

Bay 60-7550 is a selective and potent PDE2 inhibitor (Ki: 3.8 nM) that exerts positive inotropic effects on rat heart by increasing PKA-mediated phosphorylation and can be used to ameliorate cognitive impairments and memory disorders.

PF-04995274 is an effective, high-affinity, and partial serotonin 4 receptor (5-HT4R) agonist. PF-04995274 is brain penetrant and can be used for cognitive disorders associated with Alzheimer's disease. PF-04995274 has an EC50 range of 0.26-0.47 nM for hu